Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QuidelOrtho Corporation (Nasdaq: QDEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an issuer in the in vitro diagnostics and medical device manufacturing space, QuidelOrtho uses these filings to report on its financial condition, capital structure, material agreements and other significant events.
Investors can review current reports on Form 8‑K, where QuidelOrtho furnishes press releases announcing quarterly financial results, earnings conference calls and stockholder letters discussing recent performance and strategic priorities. For example, 8‑K filings in November 2025 reference third‑quarter results and a stockholder communication, while an August 21, 2025 8‑K details a Credit Agreement that established senior secured term loan A and term loan B facilities and a revolving credit facility with a syndicate of lenders.
Alongside 8‑Ks, users can also access annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide more comprehensive information on QuidelOrtho’s business, including its diagnostic segments in clinical chemistry, immunoassay, immunohematology and molecular testing. These reports typically include discussions of risk factors, research and development spending, and other elements that shape the company’s long‑term outlook.
For those interested in governance and ownership, proxy statements and beneficial ownership reports (such as Forms 3, 4 and 5) can be used to analyze executive and director holdings and transactions, although specific examples are not detailed here. Together, these documents form a record of how QuidelOrtho communicates with regulators and investors about its operations and capital decisions.
Stock Titan enhances this information by pairing real‑time EDGAR updates with AI‑powered summaries that explain the key points of long filings in plain language. Users can quickly see what each new 10‑K, 10‑Q, 8‑K or Form 4 means for QuidelOrtho without reading every page, while still having direct access to the full text for deeper review.
QuidelOrtho Corporation received an amended ownership report showing that investment adviser Rubric Capital Management LP and David Rosen together beneficially own 3,777,157 shares of QuidelOrtho common stock, representing 5.56% of the outstanding shares.
The filing states Rubric Capital advises funds that hold these shares, including Rubric Capital Master Fund LP, which has the right to receive dividends or sale proceeds on more than 5% of the stock. The securities are reported as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an open‑market purchase of common stock. On February 13, 2026, a trust associated with him bought 3,370 shares at $23.6623 per share, bringing its indirect holdings to 10,290 shares and his direct holdings to 41,412 shares.
QuidelOrtho Corp President and CEO Brian J. Blaser reported an indirect open-market purchase of common stock through a trust associated with him. On February 13, 2026, the trust bought 10,540 shares at a weighted average price of $23.5921 per share, within a range of $23.4200 to $23.9400.
After this transaction, the trust held 40,073 shares of QuidelOrtho common stock indirectly for Blaser, while he also held 25,142 shares directly. The filing notes that detailed trade-by-trade pricing is available upon request from the reporting person.
Invesco Ltd. reports beneficial ownership of 3,470,656 shares of QuidelOrtho Corp common stock, representing 5.1% of the class as of 12/31/2025. Invesco has sole voting power over 3,450,932 shares and sole dispositive power over 3,470,656 shares, with no shared powers.
The shares are held of record by clients of Invesco’s investment advisers, including Invesco Advisers, Inc. and Invesco Capital Management LLC. Invesco certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
QuidelOrtho Corporation reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year 2025 revenue was $2.73 billion, slightly below 2024, as respiratory revenue fell 20% to $402.1 million with lower COVID-19 testing, while non-respiratory revenue reached $2.33 billion.
The company posted a 2025 GAAP net loss of $1.13 billion and a GAAP operating loss of $0.92 billion, driven largely by a $701 million non-cash goodwill impairment charge. Despite this, adjusted EBITDA was $597 million with a 22% adjusted EBITDA margin, a 240 basis point improvement.
Free cash flow was $(77) million in 2025, reflecting one-time ERP system investments, but management expects free cash flow to improve by over $200 million in 2026, guiding to $120–$160 million. 2026 guidance calls for $2.7–$2.9 billion in revenue, adjusted EBITDA of $630–$670 million, and adjusted EPS of $2.00–$2.42. The company also announced that Chief Financial Officer Joseph M. Busky plans to retire effective June 30, 2026.
QuidelOrtho Corp Chief Legal Officer reports equity award vesting and tax withholding. On February 8, 2026, Michelle A. Hodges had 3,198 restricted stock units convert into an equal number of common shares at a stated price of $0, increasing her directly held stake.
In connection with this vesting, 1,148 common shares were disposed of at $29.10 per share to cover tax withholding obligations, rather than being an open-market sale. After these transactions, Hodges directly owned 41,605 shares of QuidelOrtho common stock.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported equity compensation activity involving restricted stock units and common shares. On February 8, 2026, 5,968 restricted stock units were converted into 5,968 shares of common stock at a stated price of $0.
In connection with this release, 1,806 common shares at $29.1 per share were withheld by the issuer to satisfy tax withholding obligations, leaving Busky with 41,412 common shares held directly. He also reports 6,920 common shares held indirectly by a trust.
The filing notes that 5,968 shares vested on each of February 8, 2025 and February 8, 2026, and 5,969 additional shares are scheduled to vest on February 8, 2027, reflecting an ongoing multi‑year restricted stock unit vesting schedule.
QuidelOrtho Corporation reported that board member Matthew W. Strobeck has decided not to stand for re-election at the company’s 2026 annual stockholders meeting. He will remain on the board until that meeting, after which the board size will decrease from eleven to ten directors. The company states that his decision is due to other professional commitments and not any dispute or disagreement with the company, its board, or management over operations, policies, or practices.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 5,420,217.85 shares of QuidelOrtho Corp common stock, representing 8.0% of the class as of the event date. FMR has sole voting power over 5,416,389 shares and sole dispositive power over 5,420,217.85 shares.
Abigail P. Johnson is also reported as a beneficial owner of 5,420,217.85 shares, with sole dispositive power and no voting power. The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
The filing notes that one or more other persons may receive dividends or sale proceeds from these shares, but no such person has an interest exceeding five percent of QuidelOrtho’s outstanding common stock.
QuidelOrtho Corporation’s Chief Human Resources Officer, Ronald Lee Bowman, reported equity awards on January 30, 2026. He received 36,152 restricted stock units, each representing one share of common stock, and 36,150 non-qualified stock options with a $27.17 exercise price expiring January 30, 2036.
Of the restricted stock units, 12,050 shares will vest on January 30, 2027, and the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029. The 36,150 stock options will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029. All holdings are reported as directly owned.